Clinical Trial Detail

NCT ID NCT02319044
Title Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

head and neck squamous cell carcinoma

Therapies

Durvalumab

Tremelimumab

Age Groups: adult

No variant requirements are available.